Non-opioid Pain Focus Latigo Biotherapeutics is a private clinical-stage biotechnology company focused on developing non-opioid pain medicines with a goal to stop pain transmission quickly and reduce addiction risk, presenting opportunities to position partnerships and strategic collaborations around LTG-001 and Nav1.8 inhibitors with healthcare providers, payers, and research organizations.

Lead Program LTG-001 The lead program LTG-001 is an oral Nav1.8 inhibitor targeting acute pain, suggesting sales potential in analgesic markets requiring non-opioid options, including emergency departments, postoperative care, and chronic pain adjacencies; explore investigator-led studies and potential co-development opportunities.

Strong Funding Milestones Recent Series B financing of 150 million and ongoing leadership hires signal a company in rapid growth and readiness for clinical progression, creating opportunities to align with investors, potential partnership discussions, and grant or contract avenues with government or disease-specific programs.

Strategic Leadership Expansion New CFO and chief business officer appointments, plus board additions, indicate a focus on financial discipline and strategic partnerships; leverage this for introductions to strategic investors, contract research organizations, and potential licensing or milestone-driven deal discussions.

Industry Positioning With a competitive landscape including mid-sized biotechs and opportunities in non-opioid analgesia, Latigo’s niche Nav1.8 program positions it for collaboration with clinical trial sites, contract manufacturing, and ecosystem partners, particularly those seeking innovative pain therapies and rapid-acting relief solutions.